Compare Bristol-Myers Squibb Co (BMY) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs J M Smucker Co — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while J M Smucker Co trades at $108.33 (market cap $11.63B). The key difference: Bristol-Myers Squibb Co is far larger — about 10× J M Smucker Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | SJM | |
|---|---|---|
Market Cap | $116.30B | $11.63B |
Sector | Health | Consumer Staples |
52-Week High | $62.37 | $117.05 |
52-Week Low | $42.60 | $89.53 |
Enterprise Value | $152.24B | $18.66B |
Dividend Yield | 4.42% | 4.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
SJM trades at $110.53, down 0.96% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported mixed earnings with Q4 2026 beating estimates but Q3 2025 missing, alongside a net loss of $1.23 billion in 2025. Recent news highlights Uncrustables as a growth driver, while the Twinkie acquisition faces challenges. Cash flow improved to a net positive $7.90 million in 2025, though debt-to-asset ratio rose to 43.71%.
Outlook is cautious with analyst consensus at Buy (51.61%) and a $123.18 price target, but risks include high debt, margin pressure, and FY2027 sales guidance down 3-4%. The dividend yield of about 1% offers income, but growth depends on coffee margin recovery and Uncrustables expansion amid competitive headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
